Dublin, Oct. 20, 2021 (GLOBE NEWSWIRE) -- The "Avastin (Bevacizumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn ...

Dublin, April 01, 2026 (GLOBE NEWSWIRE)-- The "Avastin (Bevacizumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's ...

Bevacizumab biosimilar LY01008 demonstrated comparative safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product Avastin when combined with paclitaxel and carboplatin in ...

Please provide your email address to receive an email when new articles are posted on . First-line anlotinib plus chemotherapy had noninferior PFS to bevacizumab plus chemotherapy for certain ...

The antiangiogenic agent bevacizumab (Avastin, Roche/Genentech) is approved for use in six different types of tumor, but most of these approvals are based on improvements in progression-free survival ...

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Third paragraph, first sentence of release the chief executive officer's name is incorrect and should read: Melissa Aucoin. The corrected release reads: ...

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus ...

Nicholas G. Anderson, MD, leads a discussion on how the first ophthalmic formulation of bevacizumab may impact the wet AMD treatment paradigm. Jim Kenney, RPh, MBA: We don’t always get extrapolation ...

Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer. The addition of PARP inhibitor olaparib (Lynparza) to bevacizumab ...